✦ LIBER ✦

Urinary excretion of TXB2 after angiotensin converting enzyme inhibition in hypertensive patients

✍ Scribed by Kei Kudo; Keishi Abe; Satoru Chiba; Ken Omata; Ko Sato; Minoru Yasugima; Makito Sato; Kaoru Yoshinaga

Book ID: 113301796
Publisher: Elsevier Science
Year: 1986
Weight: 533 KB
Volume: 21
Category: Article
ISSN: 0262-1746
DOI: 10.1016/0262-1746(86)90165-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Urinary excretion of prostacyclin and th

Urinary excretion of prostacyclin and thromboxane A2 metabolites after angiotensin converting enzyme inhibition in hypertensive patients

✍ P.H. Vlasses; R.K. Ferguson; J.B. Smith; H.H. Rotmensch; B.N. Swanson 📂 Article 📅 1983 🏛 Elsevier Science ⚖ 430 KB

CARDIAC EFFECTS OF LOCAL ANGIOTENSIN-CON

CARDIAC EFFECTS OF LOCAL ANGIOTENSIN-CONVERTING ENZYME INHIBITION IN HYPERTENSIVE PATIENTS

✍ Yoshiyuki Nakashima; Takanobu Nii; Eiichiro Tashiro; Masaharu Ikeda; Kikuo Araka 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 555 KB

Urinary angiotensin-converting enzyme 2

Urinary angiotensin-converting enzyme 2 in patients with CKD

✍ SONOO MIZUIRI; TOSHIYUKI AOKI; HIROMICHI HEMMI; MICHITSUNE ARITA; KEN SAKAI; ATS 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB

Urinary Angiotensin-Converting Enzyme 2

Urinary Angiotensin-Converting Enzyme 2 in Hypertensive Patients May Be Increased by Olmesartan, an Angiotensin II Receptor Blocker

✍ Furuhashi, M.; Moniwa, N.; Mita, T.; Fuseya, T.; Ishimura, S.; Ohno, K.; Shibata 📂 Article 📅 2014 🏛 Nature Publishing Group 🌐 English ⚖ 658 KB

Plasma atrial natriuretic peptide in ess

Plasma atrial natriuretic peptide in essential hypertension after angiotensin converting enzyme inhibition

✍ Constantine L. Papadopoulos; Basilios A. Kokkas; Panagiotis S. Kotridis; Constan 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 211 KB

Metabolic effects of long-term angiotens

Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: relationship to angiotensin-converting enzyme inhibition

✍ R. Reneland; P.-E. Andersson; A. Haenni; H. Lithell 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 566 KB

Fifty patients with mild to moderate essential hypertension were randomized to receive either 20 mg fosinopril daily for 16 weeks or placebo for 4 weeks followed by 12 weeks of 50 mg atenolol daily. Prior to these 16 weeks there was a placebo wash-out period of 2-6 weeks. Blood pressure measurements